Cargando…
Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine
Background: The adverse events reported from the COVID-19 mRNA vaccines have varied from very mild, such as pain near the vaccination site, to more severe, with occasional anaphylaxis. Details of age-specific gender differences for the adverse effects are not well documented. Methods: Age and gender...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875740/ https://www.ncbi.nlm.nih.gov/pubmed/35214694 http://dx.doi.org/10.3390/vaccines10020233 |
_version_ | 1784658005052096512 |
---|---|
author | Green, Manfred S Peer, Victoria Magid, Avi Hagani, Neta Anis, Emilia Nitzan, Dorit |
author_facet | Green, Manfred S Peer, Victoria Magid, Avi Hagani, Neta Anis, Emilia Nitzan, Dorit |
author_sort | Green, Manfred S |
collection | PubMed |
description | Background: The adverse events reported from the COVID-19 mRNA vaccines have varied from very mild, such as pain near the vaccination site, to more severe, with occasional anaphylaxis. Details of age-specific gender differences for the adverse effects are not well documented. Methods: Age and gender disaggregated data on reports of adverse events following two or three doses of the Pfizer-BioNTech COVID-19 vaccine were obtained from four cross-sectional studies. The first was from reports submitted to the Israel Ministry of Health national adverse events database (for ages 16 and above). The second was from a national cross-sectional survey based on an internet panel (for ages 30 and above), and the third and fourth were from cross-sectional surveys among employees of a large company (for ages 20–65) using links to a self-completed questionnaire. Results: In all studies, the risks of adverse events were higher following the second dose and consistently higher in females at all ages. The increased risk among females at all ages included local events such as pain at the injection site, systemic events such as fever, and sensory events such as paresthesia in the hands and face. For the combined adverse reactions, for the panel survey the female-to-male risk ratios (RRs) were 1.89 for the first vaccine dose and 1.82 for the second dose. In the cross-sectional workplace studies, the female-to-male RRs for the first, second and third doses exceeded 3.0 for adverse events, such as shivering, muscle pain, fatigue and headaches. Conclusions: The consistent excess in adverse events among females for the mRNA COVID-19 vaccine indicates the need to assess and report vaccine adverse events by gender. Gender differences in adverse events should be taken into account when determining dosing schedules. |
format | Online Article Text |
id | pubmed-8875740 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88757402022-02-26 Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine Green, Manfred S Peer, Victoria Magid, Avi Hagani, Neta Anis, Emilia Nitzan, Dorit Vaccines (Basel) Article Background: The adverse events reported from the COVID-19 mRNA vaccines have varied from very mild, such as pain near the vaccination site, to more severe, with occasional anaphylaxis. Details of age-specific gender differences for the adverse effects are not well documented. Methods: Age and gender disaggregated data on reports of adverse events following two or three doses of the Pfizer-BioNTech COVID-19 vaccine were obtained from four cross-sectional studies. The first was from reports submitted to the Israel Ministry of Health national adverse events database (for ages 16 and above). The second was from a national cross-sectional survey based on an internet panel (for ages 30 and above), and the third and fourth were from cross-sectional surveys among employees of a large company (for ages 20–65) using links to a self-completed questionnaire. Results: In all studies, the risks of adverse events were higher following the second dose and consistently higher in females at all ages. The increased risk among females at all ages included local events such as pain at the injection site, systemic events such as fever, and sensory events such as paresthesia in the hands and face. For the combined adverse reactions, for the panel survey the female-to-male risk ratios (RRs) were 1.89 for the first vaccine dose and 1.82 for the second dose. In the cross-sectional workplace studies, the female-to-male RRs for the first, second and third doses exceeded 3.0 for adverse events, such as shivering, muscle pain, fatigue and headaches. Conclusions: The consistent excess in adverse events among females for the mRNA COVID-19 vaccine indicates the need to assess and report vaccine adverse events by gender. Gender differences in adverse events should be taken into account when determining dosing schedules. MDPI 2022-02-03 /pmc/articles/PMC8875740/ /pubmed/35214694 http://dx.doi.org/10.3390/vaccines10020233 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Green, Manfred S Peer, Victoria Magid, Avi Hagani, Neta Anis, Emilia Nitzan, Dorit Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine |
title | Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine |
title_full | Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine |
title_fullStr | Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine |
title_full_unstemmed | Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine |
title_short | Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine |
title_sort | gender differences in adverse events following the pfizer-biontech covid-19 vaccine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875740/ https://www.ncbi.nlm.nih.gov/pubmed/35214694 http://dx.doi.org/10.3390/vaccines10020233 |
work_keys_str_mv | AT greenmanfreds genderdifferencesinadverseeventsfollowingthepfizerbiontechcovid19vaccine AT peervictoria genderdifferencesinadverseeventsfollowingthepfizerbiontechcovid19vaccine AT magidavi genderdifferencesinadverseeventsfollowingthepfizerbiontechcovid19vaccine AT haganineta genderdifferencesinadverseeventsfollowingthepfizerbiontechcovid19vaccine AT anisemilia genderdifferencesinadverseeventsfollowingthepfizerbiontechcovid19vaccine AT nitzandorit genderdifferencesinadverseeventsfollowingthepfizerbiontechcovid19vaccine |